Choice Hotels has a new partner in Houston-based WizeHire. Photo courtesy of Choice Hotels

A Houston startup has struck a deal with a major new client focused on getting employees back to work at its 6,000 locations worldwide.

Maryland-based international hotelier Choice Hotels International Inc. selected Houston-based WizeHire into its Qualified Vendor program as its only current recruiting solution for the thousands of franchised locations under the Choice Hotels umbrella. WizeHire provides its clients tech-enabled, customized hiring solutions and has a suite of software available for users to utilize.

"We're so excited to support Choice's independently-owned hotels with the most personal and complex part of their businesses—hiring great talent," says Sid Upadhyay, WizeHire's co-founder and CEO, in a press release.

According to data from the U.S. Bureau of Labor Statistics, the hospitality industry saw an unemployment rate of 13.5 percent. With travel expected to increase this year, Choice Hotels is looking to provide its franchisees opportunities to efficiently rehire.

"As a long-time Choice Hotels owner and WizeHire customer, I'm thrilled for what this partnership means for growing my business," says Tushar Patel, owner of Quality Inn & Suites Round Rock - Austin North, in the release.

Hospitality represents one of the six industry verticals WizeHire has listed on its website, and the startup provides "job templates created with industry experts, built-in pre-screening tools specifically for hospitality jobs and benchmarks that help identify the soft skills needed for numerous hotel roles," according to the release.

Choice Hotels nationwide will have access to these resources effective immediately, per the release.

"At a time when there is so much uncertainty for many individuals and employers in the hospitality industry, WizeHire has the opportunity to meet hiring needs at this critical moment," says Justin Nimergood, head of franchise sales for WizeHire. "I'm thrilled to be leading that charge."

After a tumultuous year in which hiring across industries essentially came to a halt, WizeHire is seeing immense business growth as companies plan to rehire, says Upadhyay in a recent interview with InnovationMap. The company recently raised a $7.5 million series A round to gear up for this growth.

With all the uncertainty last, Upadhyay says he and his team instead focused on providing resources, such as PPP loan guidance, for small businesses — something the company is focused on continuing.

"We're really going beyond just the hire," Upadhyay says in a recent episode of the Houston Innovators Podcast. "We're getting to this role where we're going to help you grow your business."

Listen to Upadhyay on the Houston Innovators Podcast:

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”